Ireland
--:--IST
Active, not recruiting Observational

Deep Learning Model and Risk Factors for Tacrolimus-related Acute Kidney Injury

NCT06596798 · tracked via the Priya Life Science China tracker
Phase
Observational
Started
2024-09-01
Last updated
2024-09-19

Condition(s) studied

AKI

Study summary

In this study, the investigators aim to develop a risk prediction model for acute kidney injury (AKI) in hospitalized patients using the calcineurin inhibitor tacrolimus. This will be achieved by mining electronic medical record data and employing explainable deep learning methods. The model will provide clinical decision support for timely intervention and treatment. Compared to traditional machine learning models, deep neural networks can extract more nuanced features from complex medical data and perform more precise pattern recognition, thereby enhancing prediction accuracy and reliability. By constructing a predictive tool based on explainable deep learning models, the investigators will better assess the association between the use of calcineurin inhibitors and AKI, explore targeted prevention strategies, and offer more precise predictions and intervention guidance to clinicians. Additionally, this research has significant socio-economic benefits and application potential. By reducing the incidence of AKI, the investigators can lower patient hospitalization duration and re-treatment costs, conserve medical resources, and improve patient quality of life. Preventive healthcare not only alleviates the physical and psychological burden on patients but also reduces the strain on the healthcare system, enhances healthcare efficiency, and promotes the rational allocation of medical resources.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Use of tacrolimus during hospitalization, with standardized therapeutic drug monitoring * Age of 18 years or older at the time of admission * Length of hospital stay ≥ hours * At least two serum creatinine level tests conducted during the hospital stay Exclusion Criteria: * Stage 5 chronic kidney disease prior to admission * Incomplete clinical data * Serum creatinine levels consistently below 40 mmol/L during hospitalization

Primary outcome measure(s)

  • AKI — From January 2020 to December 2023
    Acute kidney injury occurred after the patient took tacrolimus during hospitalization

Trial sites (1)

FacilityCityRegionStatus
The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital Jinan Shandong
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06596798 on ClinicalTrials.gov ↗ ← All trials in China